John Dever, MD
Gastroenterology · Meridian, IDNPI 1093918724
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $205 and has fallen 79.6% since, to $42 in 2025. That places this record below the midpoint for gastroenterology clinicians in ID, where the typical reported total is $1,538.
Across 15 payments — averaging $27.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mauna Kea Technologies, Inc.$97
- Takeda Pharmaceuticals U.S.A., Inc.$82
- Boston Scientific$77
- AbbVie$57
- Pfizer$26
- Braintree Laboratories, Inc.$26
- plus $49 from 3 others
What the payments were for
- Food & beverage$414100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mauna Kea Technologies, Inc. | 1 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $82 |
| Boston Scientific | 1 | $77 |
| AbbVie | 3 | $57 |
| Pfizer | 2 | $26 |
| Braintree Laboratories, Inc. | 1 | $26 |
| Sanofi | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Intercept Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$414 in reported general payments places this provider in the 25th percentile of 70 gastroenterology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mesalamine | 13 | $14,748 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 65 | $4,419 |
| Omeprazole | 126 | $1,485 |
| Ondansetron OdtOndansetron | 95 | $515 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 12 | $229 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 11 | $155 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Meridian
- Bruce CroffyMeridian$4K
- Brian StoryMeridian$2K
- Akshay GuptaMeridian$2K
- Mark Dell'aglioMeridian$550
- David JohnsonCoeur D Alene$190K
- Matthew SericatiBoise$111K
- Ashley EvansBoise$69K
- Bryan BrimhallBoise$10K
- Todd WilliamsIdaho Falls$8K
- Caleb KellyCoeur D Alene$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.